The Canadian Intellectual Property Office (”CIPO”) has communicated its intention to grant Idogen’s Patent Application No. 2,822,745. The patent belongs to Idogen’s second patent family and covers Idogen’s technology for induction of IDO for the treatment of autoimmune diseases and transplant rejection. Once the issue fee is paid by Idogen and necessary formalities have been completed by CIPO, the patent will be granted. The patent term will then extend to December 2031, potentially longer if an application for supplementary protection is filed and is granted.
Patents from this patent family were granted during 2017 in USA, Europe and Japan. The Canadian patent, when granted, will complement the granted patents in this family and an earlier European Patent in Idogen’s first patent family, granted in December 2013.
”This patent provides very important protection for our tolerogenic cell therapy in Canada, the 10th largest pharmaceutical market globally and an important territory for innovative therapies such as ours. This patent family covers key components of our technology, together with its use and its products”, Idogen´s CEO Lars Hedbys comments.
For additional information, please contact:
Lars Hedbys, CEO Idogen AB
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 4th of October 2018.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient’s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit http://www.idogen.com